Shares of Clovis Oncology Inc. (NASDAQ:CLVS) were up 2.5% during trading on Wednesday . The stock traded as high as $14.37 and last traded at $14.31, with a volume of 244,599 shares traded. The stock had previously closed at $13.96.

Several analysts have recently commented on CLVS shares. Piper Jaffray Cos. started coverage on shares of Clovis Oncology in a research report on Monday, April 4th. They set a “neutral” rating and a $18.00 price objective for the company. Mizuho reduced their price objective on shares of Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating for the company in a research report on Monday, April 11th. Zacks Investment Research downgraded shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, April 12th. Stifel Nicolaus reaffirmed a “buy” rating and set a $30.00 price objective on shares of Clovis Oncology in a research report on Tuesday, April 12th. Finally, JPMorgan Chase & Co. downgraded shares of Clovis Oncology from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $42.00 to $15.00 in a research report on Wednesday, April 13th. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $29.25.

The firm’s 50-day moving average is $14.07 and its 200 day moving average is $16.89. The company’s market cap is $556.20 million.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.39) by $0.22. During the same period in the prior year, the company posted ($1.86) earnings per share. The firm’s revenue was up NaN% on a year-over-year basis. On average, equities analysts anticipate that Clovis Oncology Inc. will post ($8.00) earnings per share for the current year.

Several institutional investors have bought and sold shares of CLVS. Rhumbline Advisers boosted its position in Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock valued at $1,058,000 after buying an additional 1,880 shares during the period. ProShare Advisors LLC boosted its position in Clovis Oncology by 9.5% in the fourth quarter. ProShare Advisors LLC now owns 36,129 shares of the biopharmaceutical company’s stock valued at $1,265,000 after buying an additional 3,125 shares during the period. California State Teachers Retirement System boosted its position in Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock valued at $1,806,000 after buying an additional 889 shares during the period. Finally, Trexquant Investment LP acquired a new position in Clovis Oncology during the fourth quarter valued at about $3,170,000.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.